A prominent biotech investor warns that current U.S. policies are creating challenges for life sciences startups. Johannes Fruehauf, a partner at VC firm Mission BioCatpial, says that these policies are leading to increased operational costs and regulatory hurdles. The investor predicts further disruptions in the sector if these issues are not addressed. Startups face difficulties in securing funding and navigating complex regulations. This environment may stifle innovation and slow down the development of new therapies and technologies. Fruehauf calls for policy reforms to support the growth and sustainability of life sciences companies. Without changes, he concludes that the U.S. risks losing its competitive edge in the global biotech landscape.
Leave a Reply